The importance of the CXCL12/CXCR4//ACKR3 axis in GBM is emphasized by multiple efforts toward the clinical translation of related inhibitors largely validated at the preclinical level [32,36,107,108,109]. This evidence concerns the gene ACKR3 and glioblastoma.